B7-H3

Ongoing clinical trials and approved products targeting B7-H3, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

Theranostic pair: this target is explored in both imaging and therapy.

6ongoing therapy trials

2ongoing imaging trials

0approved products

Target note

Full name: B7-H3 (CD276)
Nature: Transmembrane protein of the B7 family, an immune checkpoint regulator.
Normal expression: Low expression in healthy tissues.
Disease expression: Neuroblastoma, medulloblastoma, desmoplastic small round cell tumor, sarcomas, prostate, lung.
Value: Broad tumor overexpression, especially in pediatric oncology.
Approaches: Omburtamab antibody (8H9) labeled with ¹³¹I or ¹⁷⁷Lu, often given intraventricularly; antibodies and small proteins labeled with ²²⁵Ac.
Indications explored: Leptomeningeal metastases of neuroblastoma, medulloblastoma, ependymoma, desmoplastic tumors.
Points of caution: Omburtamab was not approved in the United States; data still come mostly from pediatric series.

Trial	Phase	Status	Sponsor	Countries
Omburtamab ([131I]/[177Lu])NCT04743661 · Brain (glioma, medulloblastoma…)	Phase 2	Active, not recruiting	Pediatric Brain Tumor Consortium	1
Omburtamab ([131I]/[177Lu])NCT04022213 · Sarcoma / bone	Phase 2	Active, not recruiting	Memorial Sloan Kettering Cancer Center	1
BetaBart · 177Lu-BetaBartNCT07189871 · Prostate – mCRPC	Phase 2	Recruiting	Radiopharm Theranostics, Ltd	1
BActinium-2 · [225Ac]Ac-AKY-2519 (therapeutic)NCT07887971 · Prostate – other	Phase 1	Recruiting	Aktis Oncology, Inc.	1
BActinium-1 · [225Ac]Ac-AKY-2519 (therapeutic)NCT07581184 · Prostate – mCRPC	Phase 1	Recruiting	Aktis Oncology, Inc.	1
[177Lu]DTPA-omburtamabNCT07698899 · Brain (glioma, medulloblastoma…)	Phase 1	Recruiting	Memorial Sloan Kettering Cancer Center	1

Trial	Phase	Status	Sponsor	Countries
B7-H3 tracersNCT07774533 · Sarcoma / bone	Phase 1	Recruiting	Peking University First Hospital	1
B7-H3 tracersNCT06454955 · Solid tumors (multiple indications)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	1

B7-H3. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/b7-h3/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.